Figure 1.

Kaplan-Meier curves for patients in the ibandronate/patient support programme (PSP) and alendronate groups. Time-to-failure-to-persist data for the intent-to-treat (ITT) population were used to estimate the probability of persistence at each time-point. Data for patients persisting with treatment at the end of the study were censored, to indicate that the period of observation was cut off before the event of interest (e.g. failing to persist with treatment) occurred. The censoring time was defined as the last prescription filled/dispensed plus 30 days